Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
Open Access
- 17 July 2015
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 170 (4), 675-682.e8
- https://doi.org/10.1016/j.ahj.2015.07.006
Abstract
No abstract availableKeywords
Funding Information
- Johnson and Johnson Pharmaceutical Research and Development
- Bayer HealthCare
This publication has 15 references indexed in Scilit:
- Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trialInternational Journal of Cardiology, 2015
- Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities studyHeart, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- Meta-Analysis of Cohort and Case–Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial FibrillationThe American Journal of Cardiology, 2011
- Diabetes Mellitus, Glycemic Control, and Risk of Atrial FibrillationJournal of General Internal Medicine, 2010
- Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF studyAmerican Heart Journal, 2010
- Independent predictors of stroke in patients with atrial fibrillationNeurology, 2007
- Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10‐year follow‐upDiabetes/Metabolism Research and Reviews, 2003
- Increased Levels of Tissue Plasminogen Activator Antigen and Factor VIII Activity in Nonvalvular Atrial Fibrillation: Relation to Predictors of ThromboembolismJournal of Cardiovascular Electrophysiology, 2001
- Diabetes as a risk factor for stroke. A population perspectiveDiabetologia, 1995